Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy

Talaei, M. and Robertson, N. P. ORCID: https://orcid.org/0000-0002-5409-4909 2022. Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy. Journal of Neurology 269 (1) , pp. 534-536. 10.1007/s00415-021-10908-9

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (486kB) | Preview

Abstract

Intravenous immunoglobulin (IVIg) plays a key role in treatment of inflammatory demyelinating polyneuropathies such as Guillain–Barre syndrome (GBS). However, individual response to treatment can be unpredictable, and for those most severely affected, a second dose of IVIg (SIV) is commonly administered despite limited evidence for efficacy. In this month’s journal club, we review two studies which explore the efficacy of second dosing and a third study exploring neurophysiological factors predicting relapse in chronic inflammatory polyneuropathy.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	Springer
ISSN:	0340-5354
Date of First Compliant Deposit:	16 March 2023
Date of Acceptance:	12 November 2021
Last Modified:	16 May 2023 14:40
URI:	https://orca.cardiff.ac.uk/id/eprint/157763

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item